Ποια είναι η τιμή για Healios K.K. (4593)

Η τιμή για Healios K.K. (4593) είναι $1.89

Ποια είναι η κεφαλαιοποίηση αγοράς για Healios K.K. (4593)

Η κεφαλαιοποίηση αγοράς για Healios K.K. (4593) είναι $254.55M

Healios K.K. (4593) Τιμή και Κεφαλαιοποίηση Αγοράς

Healios K.K., a Tokyo-based biopharmaceutical firm established in 2011, specializes in the discovery, development, manufacturing, and commercialization of advanced cell and regenerative medical therapies. The company operates across key markets including Japan, Europe, and the United States. Its robust pipeline features several cellular and tissue-based products, such as HLCR011 and HLCR012, which are induced pluripotent stem cell (iPSC)-derived regenerative medicines aimed at treating age-related macular degeneration. Another iPSC-based therapy, HLCL041, is being developed for metabolic liver disease. Furthermore, Healios is progressing HLCM051, a regenerative treatment designed for ischemic stroke and acute respiratory distress syndrome, alongside HLCN061 for solid tumor indications. The company also maintains a joint research partnership with Hyogo Medical University, focusing on eNK cell-based cancer immunotherapies to combat mesothelioma. Healios K.K. adopted its current name in September 2013, having previously operated under the name Retina Institute Japan, K.K.

Η τιμή για 4593	Το περιουσιακό στοιχείο B	Η κεφαλαιοποίηση αγοράς του B	Αποτελέσματα
$38,959.58 $254.55M	NVDA	$5.260T	+2,066,126.06%
$35,396.08 $254.55M	AAPL	$4.779T	+1,877,135.54%
$29,753.26 $254.55M	GOOG	$4.017T	+1,577,867.87%
$27,550.09 $254.55M	MSFT	$3.719T	+1,461,022.55%
$20,253.37 $254.55M	AMZN	$2.734T	+1,074,040.04%

Η τιμή για 4593

Το περιουσιακό στοιχείο B

Η κεφαλαιοποίηση αγοράς του B

Αποτελέσματα

$38,959.58 $254.55M